CSIMarket
 


Quidel Corporation  (QDEL)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare

Quidel's Working Capital Ratio

QDEL's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




QDEL Working Capital Ratio (Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
Y / Y Current Liabilities Change 14.37 % 169.42 % 167.66 % 63.47 % 63.21 %
Y / Y Current Assets Change 209.05 % 347.75 % 414.07 % 202.53 % 88.52 %
Working Capital Ratio MRQ 4.39 3.5 3.39 2.7 1.62
Overall Ranking # # # # #
Seq. Current Liabilities Change -42.97 % 8.9 % 62.09 % 13.61 % 34.35 %
Seq. Current Assets Change -28.46 % 12.28 % 103.66 % 88.91 % 3.65 %



Working Capital Ratio second quarter 2021 Comment
Current Liabilities decreased faster than Quidel's Current Assets, this led to improvement in Quidel's Working Capital Ratio to 4.39, Working Capital Ratio remained below Quidel Corporation average.

Within Biotechnology & Drugs industry 92 other companies have achieved higher Working Capital Ratio than Quidel in second quarter 2021. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is QDEL most successful ?
Working Capital Ratio QDEL on the trailing twelve month basis
Working Capital Ratio second quarter 2021 Company Ranking
Within: No.
Biotechnology & Drugs Industry # 93
Healthcare Sector # 338
Overall Market # 798


Working Capital Ratio Statistics
High Average Low
8.83 4.36 1.33
(Jun 30 2016)   (Mar 31 2019)




Financial Statements
Quidel's Current Liabilities $ 209 Millions Visit QDEL's Balance sheet
Quidel's Current Assets $ 918 Millions Visit QDEL's Balance sheet
Source of QDEL's Sales Visit QDEL's Sales by Geography




Companies with similar Working Capital Ratio in the quarter endingJun 30 2021, within Biotechnology & Drugs Industry Working Capital RatioJun 30 2021 MRQ Current AssetsJun 30 2021 MRQ Current Liabilities
Iovance Biotherapeutics inc   11.88 $ 666.640  Millions$ 56.106  Millions
Celldex Therapeutics inc   11.57 $ 167.606  Millions$ 14.488  Millions
Black Diamond Therapeutics Inc   11.54 $ 270.947  Millions$ 23.486  Millions
Homology Medicines Inc  11.16 $ 217.937  Millions$ 19.534  Millions
C4 Therapeutics Inc   11.10 $ 477.561  Millions$ 43.035  Millions
Neogen Corp  11.03 $ 591.451  Millions$ 53.599  Millions
Nanostring Technologies Inc   10.81 $ 466.137  Millions$ 43.123  Millions
Syndax Pharmaceuticals Inc   10.81 $ 262.555  Millions$ 24.292  Millions
Xenetic Biosciences Inc   10.64 $ 10.199  Millions$ 0.958  Millions
Lineage Cell Therapeutics Inc   10.58 $ 71.577  Millions$ 6.768  Millions
Pulmatrix Inc   10.55 $ 60.469  Millions$ 5.733  Millions
Fulgent Genetics Inc   10.45 $ 566.686  Millions$ 54.205  Millions
Adagio Therapeutics Inc   10.45 $ 396.059  Millions$ 37.897  Millions
G1 Therapeutics Inc   10.36 $ 265.700  Millions$ 25.641  Millions
Cel sci Corporation  10.01 $ 51.642  Millions$ 5.157  Millions
Adma Biologics Inc   9.70 $ 171.355  Millions$ 17.658  Millions
Vitality Biopharma Inc   9.61 $ 0.321  Millions$ 0.033  Millions
Royalty Pharma Plc  9.53 $ 2,707.454  Millions$ 283.989  Millions
Zai Lab Limited  9.33 $ 1,808.603  Millions$ 193.917  Millions
Berkeley Lights Inc   9.30 $ 255.524  Millions$ 27.486  Millions
Vaxcyte Inc   9.24 $ 301.532  Millions$ 32.637  Millions
Surface Oncology Inc   9.13 $ 170.773  Millions$ 18.696  Millions
Ayala Pharmaceuticals Inc   9.02 $ 47.010  Millions$ 5.210  Millions
Voyager Therapeutics Inc   8.94 $ 148.649  Millions$ 16.619  Millions
Ikena Oncology Inc   8.80 $ 268.710  Millions$ 30.543  Millions
Halozyme Therapeutics Inc   8.75 $ 999.750  Millions$ 114.251  Millions
Akoya Biosciences Inc   8.67 $ 157.409  Millions$ 18.161  Millions
Protagonist Therapeutics inc   8.65 $ 371.818  Millions$ 42.973  Millions
Dyadic International Inc  8.63 $ 26.156  Millions$ 3.030  Millions
Casi Pharmaceuticals inc   8.33 $ 83.505  Millions$ 10.021  Millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HYAC's Profile

Stock Price

HYAC's Financials

Business Description

Fundamentals

Charts & Quotes

HYAC's News

Suppliers

HYAC's Competitors

Customers & Markets

Economic Indicators

HYAC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071